Table 2.

Multivariate analysis of the OS, PFS and DMFS in the eligible cohort before PSM

Endpoint	Variable	Hazard ratio	95% CI	P
OS	Age (< 47 vs. ≥ 47)	2.34	(1.08-5.06)	0.031
	Clinical stage (III vs. IVa)	4.07	(1.72-9.61)	0.001
	LDH (< 275 vs. ≥ 275)	3.11	(1.37-7.06)	0.007
PFS	Clinical stage (III vs. IVa)	2.06	(1.21-3.53)	0.008
	LDH (< 275 vs. ≥ 275)	3.26	(1.77-6.02)	0.000
DMFS	Clinical stage (III vs. IVa)	2.51	(1.32-4.79)	0.005
	LDH (< 275 vs. ≥ 275)	3.49	(1.77-6.86)	0.000

PSM, propensity score-matched; OS, overall survival; PFS, progression-free survival; DMFS, distant metastasis-free survival.